Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit...
16 KB (1,223 words) - 06:43, 27 July 2024
This is a list of adverse effects of the anti-cancer drug axitinib, sorted by frequency of occurrence. Very common (>10% incidence) adverse effects include:...
4 KB (280 words) - 09:01, 27 May 2023
inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF receptors rather than...
14 KB (1,671 words) - 12:47, 23 April 2024
BCR-ABL kinase translation and promoting its degradation by protease. Axitinib, a drug used to treat renal cell carcinoma, has been shown to be effective...
29 KB (3,538 words) - 15:01, 5 December 2023
sofosbuvir/daclatasvir, osimertinib, crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag...
5 KB (232 words) - 10:23, 8 March 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
92 KB (8,667 words) - 10:57, 23 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
68 KB (5,996 words) - 02:41, 17 July 2024
biological therapies such as everolimus, torisel, nexavar, sutent, and axitinib, the use of immunotherapy including interferon and interleukin-2. Immunotherapy...
55 KB (5,119 words) - 20:31, 21 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
24 KB (1,700 words) - 04:21, 2 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
10 KB (579 words) - 06:46, 26 June 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
31 KB (3,413 words) - 23:30, 21 June 2024
progression of the cancer than pembrolizumab, axitinib and avelumab. In comparison to pembrolizumab and axitinib, it probably results in more death, but it...
100 KB (10,894 words) - 00:55, 11 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
67 KB (5,895 words) - 12:08, 7 May 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
27 KB (2,608 words) - 12:02, 19 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
17 KB (1,489 words) - 05:47, 7 April 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
63 KB (7,427 words) - 14:51, 9 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
60 KB (6,879 words) - 14:26, 16 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
24 KB (2,872 words) - 06:27, 22 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
15 KB (975 words) - 03:53, 27 June 2024
chemotherapy. In May 2019, the FDA approved avelumab in combination with axitinib for the first-line treatment of people with advanced renal cell carcinoma...
15 KB (1,447 words) - 05:05, 1 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
22 KB (1,787 words) - 05:10, 1 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
121 KB (13,799 words) - 06:42, 1 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
71 KB (6,675 words) - 12:06, 26 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
25 KB (2,086 words) - 02:24, 16 July 2024
treatment of advanced renal cell carcinoma (RCC) in adults in combination with axitinib. In June 2020, the US FDA approved a new indication for pembrolizumab as...
79 KB (7,328 words) - 01:51, 16 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
34 KB (3,021 words) - 04:42, 11 July 2024
axamozide (INN) Axberi Axberi HP Axert axicabtagene ciloleucel (INN) Axid axitinib (USAN) Axocet axomadol (USAN) Axotal Aygestin Ayradia azabon (INN) azabuperone...
11 KB (526 words) - 02:49, 1 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
28 KB (3,078 words) - 07:46, 3 June 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
13 KB (1,177 words) - 16:45, 16 July 2024
Platelet-derived growth factor (A, B, C, D) Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib...
14 KB (1,689 words) - 00:46, 6 December 2023